Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / madrigal may not be able to shrug glp 1 drugs for lo

NVO - Madrigal May Not Be Able To Shrug GLP-1 Drugs For Long

Novo Nordisk A/S

2024-06-09 08:47:48 ET

Summary

  • Eli Lilly's tirzepatide shows potential in resolving metabolic dysfunction-associated steatohepatitis without worsening fibrosis.
  • GLP-1 drugs pose a serious threat to Madrigal's Rezdiffra, potentially dominating the MASH market.
  • Madrigal's financial health is stable with sufficient funding for the launch of Rezdiffra, but profitability and market prospects remain uncertain.
  • Despite its market position, Madrigal faces substantial risks, leading to a sell recommendation.

Madrigal's Market Shake-Up: How Eli Lilly's Tirzepatide Tips the Scales

For further details see:

Madrigal May Not Be Able To Shrug GLP-1 Drugs For Long
Stock Information
Company Name: Novo Nordisk A/S
Stock Symbol: NVO
Market: NYSE
Menu
NVO NVO Quote NVO Short NVO News NVO Articles NVO Message Board
Get NVO Alerts

News, Short Squeeze, Breakout and More Instantly...